Almost half of adults and children with neurofibromatosis type 1 (NF1) responded to the investigational MEK inhibitor ...

The flow cytometry-based assay measures the expression of the protein FcyR11a as a biomarker for cardiovascular risk.

Many companies just iterate indefinitely without ever making progress toward an actual drug,” said one biotech VC on a panel ...

At an event hosted by BioPharma Dive, drugmaker executives and investors discussed the importance of focus, smart spending ...

It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.

Bayer will present three new prespecified subgroup analyses from the pivotal Phase III FINEARTS-HF cardiovascular outcomes trial investigating KERENDI ...